期刊文献+

Gastrointestinal stromal tumors and second primary malignancies before and after the introduction of imatinib mesylate 被引量:1

Gastrointestinal stromal tumors and second primary malignancies before and after the introduction of imatinib mesylate
暂未订购
导出
摘要 Gastrointestinal stromal tumor (GIST) is the most common mesenchymal malignancy of the gastrointestinal tract.GISTs may coexist with different types of cancer,either synchronous or metachronous (1).Most GISTs develop in a sporadic fashion,but familial occurrence,such as neurofibromatosis and Carney-triad,has also been reported (2).The overall frequency of second tumors in different series varied from 4.5% to 33%.The most frequent types of GIST-associated cancers were gastrointestinal carcinomas (47%),lymphoma/leukemia (7%),carcinomas of prostate (9%),breast (7%),kidney (6%),lung (5%),female genital tract (5%),carcinoid tumors (3%),soft tissue and bone sarcomas (3%),malignant melanoma (2%) and seminoma (1%) (1,3-5). Gastrointestinal stromal tumor (GIST) is the most common mesenchymal malignancy of the gastrointestinal tract.GISTs may coexist with different types of cancer,either synchronous or metachronous (1).Most GISTs develop in a sporadic fashion,but familial occurrence,such as neurofibromatosis and Carney-triad,has also been reported (2).The overall frequency of second tumors in different series varied from 4.5% to 33%.The most frequent types of GIST-associated cancers were gastrointestinal carcinomas (47%),lymphoma/leukemia (7%),carcinomas of prostate (9%),breast (7%),kidney (6%),lung (5%),female genital tract (5%),carcinoid tumors (3%),soft tissue and bone sarcomas (3%),malignant melanoma (2%) and seminoma (1%) (1,3-5).
机构地区 Department of Oncology
出处 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2013年第5期486-487,共2页 中国癌症研究(英文版)
  • 相关文献

参考文献1

二级参考文献13

  • 1[1]Hasegawa T,Matsuno Y,Shimoda T,Hirohashi S.Gastrointestinal stromal tumor:consistent CD117 immunostaining for diagnosis,and prognostic classification based on tumor size and MIB-1 grade.Hum Pathol 2002; 33:669-676
  • 2[2]Yamada T.Textbook of Gastroenterology.4th ed.Philadelphia:Lippincott Williams & Wilkins,2003; 1434
  • 3[3]Feldeman M,Scharschmidt BF,Sleisenger MH.Sleisenger &Fordtran's Gastrointestinal and Liver Disease.6th ed.Philadelphia:W.B.Saunders,1998; 751
  • 4[4]Miettinen M,Lasota J.Gastrointestinal stromal tumorsdefinition,clinical,histological,immunohistochemical,and molecular genetic features and differential diagnosis.Virchows Arch 2001;438:1-12
  • 5[5]Miettinen M,Sarlomo-Rikala M,Sobin LH,Lasota J.Gastrointestinal stromal tumors and leiomyosarcomas in the colon:a clinicopathologic,immunohistochemical,and molecular genetic study of 44 cases.Am J Surg Pathol 2000; 24:1339-1352
  • 6[6]Nishida T,Hirota S.Biological and clinical review of stromal tumors in the gastrointestinal tract.Histol Histopathol 2000; 15:1293-1301
  • 7[7]Duffaud F,Blay JY.Gastrointestinal stromal tumors:biology and treatment.Oncology 2003; 65:187-197
  • 8[8]Heinrich MC,Griffith DJ,Druker BJ,Wait CL,Ott KA,Zigler AJ.Inhibition of c-kit receptor tyrosine kinase activity by STI571,a selective tyrosine kinase inhibitor.Blood 2000; 96:925-932
  • 9[9]Buchdunger E,Cioffi CL,Law N,Stover D,Ohno-Jones S,Druker BJ,Lydon NB.Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.J Pharmacol Exp Ther 2000; 295:139-145
  • 10[10]Druker BJ,Tamura S,Buchdunger E,Ohno S,Segal GM,Fanning S,Zimmermann J,Lydon NB.Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.Nat Med 1996; 2:561-566

共引文献17

同被引文献7

引证文献1

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部